Stephen Willey
Stock Analyst at Stifel
(3.52)
# 926
Out of 4,944 analysts
134
Total ratings
43.16%
Success rate
7.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Maintains: Buy | $8 → $7 | $4.60 | +52.17% | 6 | Aug 8, 2025 | |
| EXEL Exelixis | Maintains: Hold | $38 → $41 | $38.32 | +6.99% | 19 | Jul 29, 2025 | |
| CELC Celcuity | Reinstates: Buy | $30 | $50.60 | -40.71% | 1 | Jul 1, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $28 | $13.90 | +101.44% | 1 | Jun 25, 2025 | |
| INCY Incyte | Upgrades: Buy | $75 → $107 | $85.60 | +25.00% | 6 | Jun 16, 2025 | |
| MGNX MacroGenics | Maintains: Hold | $6 → $5 | $1.62 | +208.64% | 3 | May 14, 2025 | |
| BOLT Bolt Biotherapeutics | Maintains: Hold | $25 → $20 | $5.68 | +252.11% | 4 | May 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $36 → $35 | $10.27 | +240.80% | 5 | Apr 9, 2025 | |
| NKTX Nkarta | Maintains: Buy | $15 → $14 | $2.11 | +563.51% | 3 | Mar 27, 2025 | |
| VOR Vor Biopharma | Maintains: Buy | $12 → $5 | $1.97 | +153.81% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.41 | +183.69% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $97 → $96 | $125.00 | -23.20% | 6 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $27 → $2.5 | $1.28 | +95.31% | 7 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $120 | $2.68 | +4,377.61% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $28 | $13.84 | +102.31% | 6 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $11.10 | +323.42% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $0.83 | +383.97% | 7 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $34 → $3 | $2.07 | +44.93% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $7 | $5.00 | +40.00% | 10 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $1.46 | +173.97% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $37.30 | +66.22% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $3.02 | +198.01% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.06 | +482.52% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $1.64 | +17,514.68% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $1.97 | +965.99% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $1.14 | +250.88% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $431.12 | -71.47% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $42.47 | +10.67% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $57.37 | +89.99% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $20.68 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $5.98 | +284.62% | 5 | Feb 7, 2018 |
AbCellera Biologics
Aug 8, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $4.60
Upside: +52.17%
Exelixis
Jul 29, 2025
Maintains: Hold
Price Target: $38 → $41
Current: $38.32
Upside: +6.99%
Celcuity
Jul 1, 2025
Reinstates: Buy
Price Target: $30
Current: $50.60
Upside: -40.71%
Crescent Biopharma
Jun 25, 2025
Initiates: Buy
Price Target: $28
Current: $13.90
Upside: +101.44%
Incyte
Jun 16, 2025
Upgrades: Buy
Price Target: $75 → $107
Current: $85.60
Upside: +25.00%
MacroGenics
May 14, 2025
Maintains: Hold
Price Target: $6 → $5
Current: $1.62
Upside: +208.64%
Bolt Biotherapeutics
May 13, 2025
Maintains: Hold
Price Target: $25 → $20
Current: $5.68
Upside: +252.11%
Nurix Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $36 → $35
Current: $10.27
Upside: +240.80%
Nkarta
Mar 27, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $2.11
Upside: +563.51%
Vor Biopharma
Mar 21, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $1.97
Upside: +153.81%
Feb 27, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.41
Upside: +183.69%
Feb 21, 2025
Maintains: Buy
Price Target: $97 → $96
Current: $125.00
Upside: -23.20%
Jan 10, 2025
Downgrades: Hold
Price Target: $27 → $2.5
Current: $1.28
Upside: +95.31%
Nov 14, 2024
Maintains: Buy
Price Target: $150 → $120
Current: $2.68
Upside: +4,377.61%
Oct 28, 2024
Maintains: Buy
Price Target: $21 → $28
Current: $13.84
Upside: +102.31%
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $11.10
Upside: +323.42%
Aug 20, 2024
Maintains: Buy
Price Target: $8 → $4
Current: $0.83
Upside: +383.97%
Jul 9, 2024
Downgrades: Hold
Price Target: $34 → $3
Current: $2.07
Upside: +44.93%
Apr 12, 2024
Maintains: Hold
Price Target: $7
Current: $5.00
Upside: +40.00%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $1.46
Upside: +173.97%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $37.30
Upside: +66.22%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $3.02
Upside: +198.01%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $2.06
Upside: +482.52%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $1.64
Upside: +17,514.68%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $1.97
Upside: +965.99%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $1.14
Upside: +250.88%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $431.12
Upside: -71.47%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $42.47
Upside: +10.67%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $57.37
Upside: +89.99%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $20.68
Upside: -
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $5.98
Upside: +284.62%